Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIS phase I study of indisulam alone and with irinotecan in refractory pediatric solid tumors
jRCT2031260508Phase 1Not yet recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2026
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of indisulam and irinotecan in Non-hematologic malignancy (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of dose-limiting toxicity. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
indisulamirinotecan
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031260508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260508.